Larry Tsai
Nessuna posizione attualmente
Profilo
Larry Tsai worked as Vice President-Research & Development at Aeris Therapeutics LLC from 2002 to 2011.
He then worked as Chief Medical Officer at Tetraphase Pharmaceuticals, Inc. from 2018 to 2019.
Tsai received his undergraduate degree from Stanford University and his doctorate degree from Massachusetts Institute of Technology.
Precedenti posizioni note di Larry Tsai
Società | Posizione | Fine |
---|---|---|
TETRAPHASE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 24/06/2019 |
Aeris Therapeutics LLC
Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Chief Tech/Sci/R&D Officer | 01/01/2011 |
Formazione di Larry Tsai
Stanford University | Undergraduate Degree |
Massachusetts Institute of Technology | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Aeris Therapeutics LLC
Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Larry Tsai